Project Description

Title: Efficacy and Safety of Tirzepatide in Type 2 Diabetes Mellitus and Obesity Management: A Real Word Evidence

Author: Selim et al.


The concurrent presence of type 2 diabetes mellitus (T2DM) and obesity represents a significant public health challenge, due to subsequent burden of multiple morbidities and associated mortality. Tirzepatide, a dual Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptor which is a once-weekly injectable medication, has been demonstrated as a promising therapeutic strategy to combat both of these conditions in certain clinical trials. The present study aims to assess the real-world effectiveness and safety of tirzepatide in managing T2DM and obesity in Bangladesh. It will be conducted as an observational study over a period of 12 months at the Department of Endocrinology, Bangladesh Sheikh Mujib Medical University (BSMMU). A total of 609 adult T2DM patients, currently on anti-diabetic medication, will be enrolled according to inclusion and exclusion criteria and following informed written consent. Glycemic control will be evaluated using HbA1C serum levels, while obesity management will be assessed through changes in body weight and body mass index (BMI). Data will be collected through face-to-face interviews, physical examinations, and laboratory investigations, meticulously recorded in separated case record forms. After enrollment, patients will undergo three follow-up assessments at the 14th day, at end of 3rd month and at end of 6th month along with monitoring of any adverse events. Data analysis will be conducted using SPSS V-25. The study will strictly adhere to the ethical principles outlined in the ‘Declaration of Helsinki’.

Status: Ongoing

Full text link: Not available